Cargando…

Cardiovascular Risk with Non-steroidal Anti-inflammatory Drugs: Clinical Implications

In February 2014, the US Food and Drug Administration (FDA) convened an advisory committee meeting to discuss the accumulated data relating to the cardiovascular risk of non-steroidal anti-inflammatory drugs (NSAIDs) and the potential implications on the class prescription labeling. The committee re...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bello, Alfonso E., Holt, Robert J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2014
Materias:	Current Opinion
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4206767/ https://www.ncbi.nlm.nih.gov/pubmed/25079141 http://dx.doi.org/10.1007/s40264-014-0207-2

Ejemplares similares

Evolution of Drug Resistance in Tuberculosis: Recent Progress and Implications for Diagnosis and Therapy
por: Trauner, Andrej, et al.
Publicado: (2014)

Implications of Non-Specific Effects for Testing, Approving, and Regulating Vaccines
por: Benn, Christine Stabell, et al.
Publicado: (2023)

Lipoprotein(a) as a cardiovascular risk factor: current status
por: Nordestgaard, Børge G., et al.
Publicado: (2010)

Differential epigenetic factors in the prediction of cardiovascular risk in diabetic patients
por: Napoli, Claudio, et al.
Publicado: (2020)

The Underrated Risks of Tamoxifen Drug Interactions
por: Hansten, Philip D.
Publicado: (2018)

Non-Steroidal Anti-Inflammatory Drugs: An Overview of Cardiovascular Risks
por: Meek, Inger L., et al.
Publicado: (2010)

Drug Exposure and the Risk of Microscopic Colitis: A Critical Update
por: Lucendo, Alfredo J.
Publicado: (2017)

Multiple Sclerosis Disease-Modifying Therapy and the COVID-19 Pandemic: Implications on the Risk of Infection and Future Vaccination
por: Zheng, Crystal, et al.
Publicado: (2020)

Global position paper on cardiovascular regenerative medicine
por: Fernández-Avilés, Francisco, et al.
Publicado: (2017)

Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management
por: Chapman, M. John, et al.
Publicado: (2011)

Clinical Implications of the 2013 ESH/ESC Hypertension Guidelines: Targets, Choice of Therapy, and Blood Pressure Monitoring
por: Kjeldsen, Sverre E., et al.
Publicado: (2014)

Quality markers in cardiology: measures of outcomes and clinical practice—a perspective of the Spanish Society of Cardiology and of Thoracic and Cardiovascular Surgery
por: López-Sendón, José-Luis, et al.
Publicado: (2016)

UK Biobank: opportunities for cardiovascular research
por: Littlejohns, Thomas J, et al.
Publicado: (2019)

The continuum of personalized cardiovascular medicine: a position paper of the European Society of Cardiology
por: Kirchhof, Paulus, et al.
Publicado: (2014)

Cardiovascular Safety Profile of Dapoxetine during the Premarketing Evaluation
por: Kowey, Peter R., et al.
Publicado: (2012)

Clinical Drug Development in Epilepsy Revisited: A Proposal for a New Paradigm Streamlined Using Extrapolation
por: Wadsworth, Ian, et al.
Publicado: (2016)

Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel
por: Ference, Brian A., et al.
Publicado: (2017)

Limitations of the SCORE-guided European guidelines on cardiovascular disease prevention
por: Mortensen, Martin Bødtker, et al.
Publicado: (2017)

Drug Repurposing of Generic Drugs: Challenges and the Potential Role for Government
por: van der Pol, Karel H., et al.
Publicado: (2023)

The Diversity of Biosimilar Design and Development: Implications for Policies and Stakeholders
por: Grampp, Gustavo, et al.
Publicado: (2015)

EuGMS Task and Finish group on Fall-Risk-Increasing Drugs (FRIDs): Position on Knowledge Dissemination, Management, and Future Research
por: Seppala, L. J., et al.
Publicado: (2019)

Cardiovascular Disease and Use of Renin-Angiotensin System Inhibitors in COVID-19
por: Kow, Chia Siang, et al.
Publicado: (2020)

Myxosporean parasites in Australian frogs: Importance, implications and future directions
por: Hartigan, Ashlie, et al.
Publicado: (2013)

A Science-Based Methodology Framework for the Assessment of Combination Safety Risks in Clinical Trials
por: Patera, Andriani C., et al.
Publicado: (2023)

Tinzaparin Sodium Pharmacokinetics in Patients with Chronic Kidney Disease: Practical Implications
por: Helfer, Hélène, et al.
Publicado: (2019)

Fasting is not routinely required for determination of a lipid profile: clinical and laboratory implications including flagging at desirable concentration cut-points—a joint consensus statement from the European Atherosclerosis Society and European Federation of Clinical Chemistry and Laboratory Medicine
por: Nordestgaard, Børge G., et al.
Publicado: (2016)

Antipsychotic-Induced Metabolic and Cardiovascular Side Effects in Schizophrenia: A Novel Mechanistic Hypothesis
por: Scigliano, Giulio, et al.
Publicado: (2013)

The Risk of Thrombocytopenia During Valproic Acid Therapy: A Critical Summary of Available Clinical Data
por: Buoli, Massimiliano, et al.
Publicado: (2017)

Trauma of abortion restrictions and forced pregnancy: urgent implications for acute care surgeons
por: Keegan, Grace, et al.
Publicado: (2023)

Omega-3 Fatty Acid Formulations in Cardiovascular Disease: Dietary Supplements are Not Substitutes for Prescription Products
por: Fialkow, Jonathan
Publicado: (2016)

Insights Into the Results of Sotagliflozin Cardiovascular Outcome Trials: Is Dual Inhibition the Cherry on the Cake of Cardiorenal Protection?
por: Koufakis, Theocharis, et al.
Publicado: (2021)

eClinic: increasing use of telehealth as a risk reduction strategy during the covid-19 pandemic
por: Kemp, Michael T, et al.
Publicado: (2020)

Chloroquine for SARS-CoV-2: Implications of Its Unique Pharmacokinetic and Safety Properties
por: Smit, Cornelis, et al.
Publicado: (2020)

Artificial Intelligence and the Future of the Drug Safety Professional
por: Danysz, Karolina, et al.
Publicado: (2018)

Policy Options for Infliximab Biosimilars in Inflammatory Bowel Disease Given Emerging Evidence for Switching
por: Husereau, Don, et al.
Publicado: (2018)

Pharmacokinetics and Generic Drug Switching: A Regulator’s View
por: Glerum, Pieter J., et al.
Publicado: (2020)

Anti-Amyloid Monoclonal Antibodies are Transformative Treatments that Redefine Alzheimer's Disease Therapeutics
por: Cummings, Jeffrey
Publicado: (2023)

Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel
por: Borén, Jan, et al.
Publicado: (2020)

Penetrating deep pelvic injury due to “less-lethal” beanbag munitions: a case report and policy implications
por: Schenck, Christopher S, et al.
Publicado: (2021)

Antimicrobial Agents are Societal Drugs: How Should This Influence Prescribing?
por: Sarkar, Paul, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_l1b5mjk64krar8p5j5bvsujm6v